Literature DB >> 17964703

Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats.

Hanaa H Ahmed1, Sekena H Abd El-Aziem, Mosaad A Abdel-Wahhab.   

Abstract

The use of nitrofurans as veterinary drugs has been banned in the EU since 1993 due to doubts on the safety of the protein-bound residues of these drugs in edible products. Furazolidone (FUZ) is a nitrofuran drug, which has been used for many years as an antibacterial drug in veterinary practice. The aim of the current study is to investigate the role of L-cysteine and L-methionine in the protection against hormonal imbalance and the genotoxicity induced by FUZ using the micronucleus (MN) assay and random amplified polymorphism DNA (RAPD-PCR) analysis in female rats. Forty female Sprague-Dawley rats were divided into four groups included the untreated control group; a group treated with FUZ (300 mg/kg b.w.); a group treated with a mixture of L-cysteine (300 mg/kg b.w.) and L-methionine (42.8 mg/kg b.w.) and a group treated with FUZ plus the mixture of L-cysteine and L-methionine for 10 days. The results indicated that FUZ induced hormonal disturbances involving thyroid, ovarian and adrenal hormones. Moreover, FUZ increased the micronucleus formation and induced changes in polymorphic band patterns. The combined treatment with FUZ and the mixture of L-cysteine and L-methionine succeeded to prevent or diminish the endocrine disturbance and the clastogenic effects of FUZ. The current study is casting new light on the complex mechanisms underlying the ameliorating action of dietary L-cysteine and L-methionine against FUZ toxicity in experimental animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964703     DOI: 10.1016/j.tox.2007.09.018

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  4 in total

1.  Is furazolidone therapy for Helicobacter pylori effective and safe?

Authors:  Vincenzo De Francesco; Enzo Ierardi; Cesare Hassan; Angelo Zullo
Journal:  Dig Dis Sci       Date:  2009-02-20       Impact factor: 3.199

2.  Furazolidone therapy for Helicobacter pylori: is it effective and safe?

Authors:  Vincenzo De Francesco; Enzo Ierardi; Cesare Hassan; Angelo Zullo
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

Review 3.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

4.  Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication.

Authors:  Ya-Wen Zhang; Wei-Ling Hu; Yuan Cai; Wen-Fang Zheng; Qin Du; John J Kim; John Y Kao; Ning Dai; Jian-Min Si
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.